Avandia Advisory Cmte. Is FDA's Primary Response To Congressional Pressure
Executive Summary
Sponsors will get another look in July at how FDA interprets guidance for assessing the cardiovascular risk of diabetes drugs in clinical trials. The venue will be a meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees
You may also be interested in...
Avandia Advisory Committee Re-Review Reflects Well On FDA
The FDA advisory committee re-review of cardiovascular safety risks with GlaxoSmithKline's Avandia (rosiglitazone) will not end calls from agency critics to create a separate drug safety center. However, the transparency of internal scientific disputes on display at the July 13-14 meeting and the committee's recommendations could take some ammunition away from those who assert the Center for Drug Evaluation and Research has given short shrift to safety issues
Avandia Advisory Committee Re-Review Reflects Well On FDA
The FDA advisory committee re-review of cardiovascular safety risks with GlaxoSmithKline's Avandia (rosiglitazone) will not end calls from agency critics to create a separate drug safety center. However, the transparency of internal scientific disputes on display at the July 13-14 meeting and the committee's recommendations could take some ammunition away from those who assert the Center for Drug Evaluation and Research has given short shrift to safety issues
GSK Settles Hundreds Of Avandia Suits Before FDA Advisory Cmte. Meeting
The upcoming FDA advisory committee meeting on Avandia (rosiglitazone) may be putting pressure on GlaxoSmithKline to settle a chunk of the product liability suits facing the company